The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma.
 
Gulam Abbas Manji
Honoraria - Celgene; Cend Therapeutics; Exelixis; Roche/Genentech
Consulting or Advisory Role - Cend Therapeutics; Exelixis; Ipsen; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Michael S. May
No Relationships to Disclose
 
Ilenia Pellicciotta
No Relationships to Disclose
 
Sarah Sta Ana
No Relationships to Disclose
 
Naomi Sender
No Relationships to Disclose
 
Samuel M Pan
No Relationships to Disclose
 
Isabelle Ross
No Relationships to Disclose
 
Jianhua Hu
No Relationships to Disclose
 
Qian Shi
Honoraria - Chugai Pharma
Consulting or Advisory Role - Hoosier Cancer Research Network; Kronos Bio; Mirati Therapeutics; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Alexander G Raufi
No Relationships to Disclose